Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC). A Phase II Study of GV 1001 Telomerase Peptide Vaccination in Patients With Locally Advanced NSCLC
Survival in patients with locally advanced, inoperable NSCLC may be improved if local
control can be achieved with concurrent chemo radiotherapy .After completed standard
chemo-and radiation therapy; the safety and efficacy of vaccination therapy will be measured
as time to progression after treatment with GV1001. Analysis of changes in T-cell
subpopulations and cytokines in peripheral blood will be performed.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To examine if combined chemoradiotherapy in patients with NSCLC followed by vaccination( immunotherapy) will increase the immunological response compared to previous experience
Steinar Aamdal
Principal Investigator
Oslo University Hospital
Norway: Norwegian Medicines Agency
2006-002646 11
NCT00509457
November 2006
August 2009
Name | Location |
---|